The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program 1 —introduced a discussion draft of a bill that would modify the ...
On February 2, 2024, six senators known as the “Gang of Six” – John Thune, Debbie Stabenow, Shelley Moore Capito, Tammy Baldwin, Jerry Moran and Ben Cardin – released a discussion draft bill intended ...
Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...
Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...
The drug industry and hospitals have been butting heads over the future of a federal drug pricing program for more than a year, according to The Washington Post. Federal regulators may finalize ...
The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.
In May 2025, Gov. Jared Polis signed Senate Bill 71 into law, dramatically expanding Colorado’s participation in the 340B Drug Pricing Program by preventing any limitations on the number of pharmacies ...
The 340B drug pricing program is complicated. A clinic leader and a hospital said that’s making it easy for there to be misunderstandings about if the savings are being passed onto the patient.
Congress needs to act to bring needed reforms into the 340B to make revenue from the drug pricing program more transparent and to ensure patients are benefiting from the discounts, according to a ...
The 340B Drug Pricing Program was developed more than three decades ago to help improve access to medicines for vulnerable patients 4 via manufacturer discounts to specific nonprofit hospitals and ...
In August, J&J informed disproportionate share hospitals, which care for a large number of vulnerable patients, that it would stop giving them upfront discounts on plaque psoriasis treatment Stelara ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results